GLP-1 Maintenance Dose: What the Research Says About Lowering It

Yes, a GLP-1 dose can sometimes be lowered after weight loss, and the strongest evidence so far comes from a 112-week trial called SURMOUNT-MAINTAIN. In that study, people who stepped down from tirzepatide at their maximum tolerated dose to 5 mg weekly kept a model-based weight change of -16.6% from baseline, compared with -9.9% for those switched to placebo ^[3]. The drug labels for Wegovy and Zepbound also list more than one approved maintenance dose, chosen by response and tolerability ^[1][2]. Spacing injections out to every other week or longer has much weaker evidence: one retrospective case series of 30 adults and computer simulations, not large randomized trials ^[7][10][11].

Two pieces of evidence point the same way on stopping entirely. In SURMOUNT-MAINTAIN, 67% of the placebo group needed rescue tirzepatide because they regained more than half their lost weight, compared with 25% of the 5 mg group ^[3]. And a joint guidance statement from three obesity medicine organizations gives a strong recommendation to continue obesity medications during weight maintenance ^[21]. Any change to a dose or schedule is a decision to make with a prescriber, not something to do alone ^[15].

What maintenance doses does the Wegovy label allow?

Wegovy starts at 0.25 mg once weekly for 4 weeks, then the dose goes up every 4 weeks on an escalation schedule until it reaches the maintenance dosage ^[1]. For weight reduction in adults, the label lists two maintenance options: 1.7 mg or 2.4 mg (the recommended dose) once weekly ^[1].

The label also covers two other situations. For patients who tolerate 2.4 mg for at least 4 weeks and for whom additional weight reduction is clinically indicated, the dose may be increased to a maximum of 7.2 mg, sold as Wegovy HD ^[1]. For MASH, the maintenance dosage is 2.4 mg, and patients who do not tolerate it can decrease to 1.7 mg ^[1]. For cardiovascular risk reduction, the maintenance dosage is 2.4 mg (recommended) or 1.7 mg ^[1].

So 1.7 mg is an approved maintenance dose for weight reduction, not just a stepping stone on the way to 2.4 mg ^[1].

What maintenance doses does Zepbound allow?

Zepbound starts at 2.5 mg once weekly for 4 weeks. The label states plainly that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage ^[2]. Eli Lilly repeats this in its pricing announcement: the 2.5 mg dose is a starting dose, and the recommended maintenance doses are 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term maintenance ^[20].

For obstructive sleep apnea, the recommended maintenance dosage is 10 mg or 15 mg once weekly ^[2]. The maximum is 15 mg weekly, and dose increases happen in 2.5 mg steps after at least 4 weeks on the current dose ^[2]. The label also says that if a patient does not tolerate a maintenance dosage, a lower maintenance dosage is an option ^[2].

Both labels say the maintenance dosage should be chosen by considering treatment response and tolerability ^[1][2].

What did SURMOUNT-MAINTAIN find about lowering tirzepatide to 5 mg?

SURMOUNT-MAINTAIN was a phase 3b trial that ran 112 weeks across 20 US sites, published in The Lancet (epub May 12, 2026; issue June 6, 2026) and funded by Eli Lilly ^[3]. It had two parts: a 60-week open-label weight-loss period on tirzepatide at the maximum tolerated dose (10 mg or 15 mg), followed by a 52-week double-blind maintenance period ^[3].

A total of 441 patients took at least one dose during the weight-loss period. At week 60, 378 participants were randomly assigned in a 3:3:2 ratio: 140 continued the maximum tolerated dose, 144 dropped to 5 mg, and 94 switched to placebo ^[3]. Starting at week 84, participants could receive rescue tirzepatide if their weight regain exceeded 50% of what they had lost ^[3]. At baseline, participants had a mean body weight of 113.8 kg, a BMI of 40.1, a mean age of 46.6, and 65% were female ^[3].

The model-based weight change from baseline to week 112:

Group	Weight change from baseline	Difference vs placebo	Needed rescue therapy
Continued maximum tolerated dose	-21.9%	-12.0%	11 of 138 (8%)
Lowered to 5 mg	-16.6%	-6.6%	35 of 142 (25%)
Switched to placebo	-9.9%	—	60 of 90 (67%)

All comparisons reached p<0.0001 ^[3]. 345 of 378 participants (91%) completed the study. The most common adverse events were gastrointestinal, mostly mild to moderate, and mostly occurred during dose escalation ^[3].

The authors’ reading: continuing at the maximum tolerated dose maintained weight reduction and health-related benefits; dropping to 5 mg might be a valuable alternative to discontinuation, though individual responses vary; and long-term treatment is often necessary to maintain weight reduction ^[3].

Can switching from an injection to a daily pill keep weight off?

There is now trial evidence for one version of this: switching from an injectable to orforglipron, a once-daily oral GLP-1 receptor agonist that the trial paper described as under investigation for obesity and type 2 diabetes. The ATTAIN-MAINTAIN trial took participants from the SURMOUNT-5 study who had been treated with tirzepatide (cohort 1, n=205) or semaglutide (cohort 2, n=171) and randomized them to orforglipron once daily or placebo for 52 weeks ^[4].

Among participants who had reached a weight plateau, the share of their prior weight reduction that was maintained at week 52 was 74.7% with orforglipron versus 49.2% with placebo in cohort 1, and 79.3% versus 37.6% in cohort 2 ^[4]. These are shares of prior weight reduction maintained, not percent changes in body weight.

The trial has limits: there was no comparator arm continuing the injectable, it lasted one year, and all sites were in the USA ^[4]. A commentary published in Diabetes, Obesity and Metabolism frames the field as moving from an induction phase to maintenance, with three hypothesized options: continued injectable therapy at a lower dose, a switch to an oral GLP-1 agent, or discontinuation. Its thresholds, such as maintaining at least 75% of induction loss, are illustrative and intended to be hypothesis-generating rather than clinical targets ^[5].

Does taking a GLP-1 every other week keep weight off?

The idea came from patients. Mitch Biermann, a physician at Scripps, said patients told him they were spacing out their injections on their own and still holding their weight, and he began recommending it to people who wanted to de-escalate ^[6][9]. He noted there is no current standard of care for how to de-escalate ^[6].

He and colleagues published a retrospective case series in the journal Obesity in 2026: 30 adults who had hit a weight plateau on weekly semaglutide or tirzepatide moved to reduced-frequency dosing at their existing dose ^[7]. The schedules varied: 17 injected every 2 weeks, 6 every 10 to 14 days, and 7 stretched beyond 2 weeks, with the longest gap reaching six weeks ^[8][9]. They stayed on reduced frequency for a mean of 36.3 weeks ^[7].

Average weight went from 87.9 kg before treatment to 74.1 kg at plateau, then to 72.4 kg on reduced-frequency dosing (p<0.01) ^[7]. Four of the 30 regained weight and went back to weekly dosing; most had been on non-maximal doses, averaging 7.5 mg tirzepatide or 1.7 mg semaglutide ^[6].

Metabolic and body composition results held up as well. A1c improved from 5.6% before treatment to 5.1% on weekly dosing and stayed there on reduced frequency. Triglycerides fell from 121 to 84.3 mg/dL on weekly dosing and sat at 74.8 on reduced frequency. Mean arterial pressure went from 90.5 to 84.8 mm Hg, then 85.1 ^[8]. Total and truncal fat fell while skeletal muscle mass held steady ^[7].

The study has real limits. Only four participants were not white, only two had class II or III obesity, most were privately insured, and there was no control group ^[8][9].

What do obesity specialists say about spacing doses out?

Kimberly Gudzune, chief medical officer of the American Board of Obesity Medicine, called it a small study and said more data is needed to understand the right approach for different patients. If a reduced frequency is tried, she said, there needs to be very close follow-up so people do not lose the health benefits they gained. She also cautioned that this population had dramatic weight and metabolic results, which may not generalize ^[6].

Fatima Stanford, an obesity specialist at Harvard Medical School, noted that people who agree to reduce treatment frequency may already be more adherent or more metabolically responsive. Still, she said the study reframes the conversation: chronic treatment does not necessarily mean maximal weekly dosing forever ^[9].

Biermann’s own interpretation is that maintenance may need far less hormone than weight loss does ^[8].

What do computer models predict about spaced-out dosing?

Two papers by Anıl Cengiz, Calvin Wu, and Sean Lawley built pharmacokinetic-pharmacodynamic models of virtual patients to simulate weight change at different dosing frequencies (published in Obesity in 2025 and in Diabetes, Obesity and Metabolism in 2025) ^[10][11]. These are simulated predictions for virtual patients, not results from clinical trials.

For semaglutide 2.4 mg, the model predicts a steady-state weight reduction of 17% with weekly dosing versus 12% with one dose every 2 weeks. That means half the drug taken over time, with 72% of the weight loss retained ^[10][11].

For tirzepatide, the model predicts steady-state reductions of 17%, 21%, and 23% at 5, 10, and 15 mg weekly, versus 12%, 16%, and 18% at those same doses every 2 weeks, so roughly 75% of the loss is retained ^[11]. Once-monthly dosing was predicted to retain nearly 50% of the weight loss ^[11].

The authors themselves flag the approach as off-label and lacking broad clinical validation, and they describe testing an every-14-day schedule in a clinical trial as a natural next step ^[10].

What is “microdosing,” and is there any evidence for it?

Microdosing is not a medical term, said Amanda Velazquez, director of Obesity Medicine at Cedars-Sinai. She said there is no evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss or broader health benefits ^[12].

Her Cedars-Sinai colleague Jeremy Korman noted that wellness and weight loss companies often define a microdose arbitrarily as 25% of a standard dose, even though there is no standard dose for GLP-1s ^[12]. The Cedars-Sinai article reports that at very low doses, weight loss tends to be modest, around 5% to 6%. Korman said the dramatic results people see with GLP-1s—15% to 20% body weight loss—happen at higher doses, and that maintenance typically uses midrange doses, not very low ones ^[12].

Jody Dushay, an endocrinologist at Harvard Medical School and Beth Israel Deaconess, wrote in a May 29, 2026 opinion column that there is no single definition of microdosing and no legitimate long-term data to support it ^[13].

The practice is common, though. The Los Angeles Times reported in June 2026 that telehealth companies including Fridays, Noom, and Found Health began offering lower-dose protocols in 2025, and that Sara Siavoshi, a board-certified obesity specialist, estimates 30% to 40% of her roughly 5,000 patients are microdosing tirzepatide or semaglutide ^[14].

What are the risks of microdosing and compounded products?

W. Scott Butsch of Cleveland Clinic, quoted in an article published July 31, 2026, does not recommend microdosing. He explained that with a reduced dose, the drug can leave the system faster than intended, so side effects like nausea and diarrhea can keep recurring with each dose. Accidental overdose is another risk, especially with compounded versions, and microdosing is not endorsed by the American Diabetes Association ^[15].

The FDA has documented dosing errors with compounded semaglutide sold in multi-dose vials. In the majority of reports, patients drew up and injected 5 to 20 times the intended dose, and the FDA says confusion between units, milligrams, and milliliters may have contributed. Some patients needed hospitalization, and reported events included fainting, dehydration, acute pancreatitis, and gallstones ^[16].

As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency cautions that these reports do not establish causation and that the totals are likely undercounts ^[17].

A brief report written for nurse practitioners describes subtherapeutic microdosing as driven by gastrointestinal tolerability and by patients pursuing what the authors call “vanity weight,” and points to the safety risks of pen manipulation, compounded vials, and medication sharing ^[25].

Is supervised fractional pen dosing different from online microdosing?

There is a distinct practice described in the clinical literature: taking a fraction of an approved dose from a multidose semaglutide pen by counting clicks. Authors from UNC Health writing in Diabetes Care in 2025 noted that each multidose pen delivers about 72 unnumbered clicks of medication, and listed the situations where clinicians use fractional dosing: titration or taper, severe gastrointestinal side effects, and patients paying cash who want to extend each pen ^[18].

The same authors are direct about the evidence: this method is off-label, is not endorsed by the manufacturer, has no clinical trials validating its safety or efficacy, and requires close monitoring ^[18].

Cedars-Sinai draws the same line from the other side: lower doses of FDA-approved GLP-1 medications used under supervision as part of titration are standard medical practice, and that is not the same as the microdosing strategies promoted online ^[12].

Does a lower maintenance dose cost less?

For Wegovy pens through the NovoCare self-pay standard offer, no. Every pen dose from 0.25 mg through 2.4 mg is $349 per month, where a month is defined as one box of 4 pens. Wegovy HD at 7.2 mg is $399 per month. New patients pay $199 per month for their first two fills of the 0.25 mg and 0.5 mg doses ^[19].

Wegovy pen dose	NovoCare self-pay standard offer
0.25 mg	$349/month
0.5 mg	$349/month
1 mg	$349/month
1.7 mg	$349/month
2.4 mg	$349/month
7.2 mg (Wegovy HD)	$399/month

For Zepbound single-dose vials through the LillyDirect Self Pay Journey program, announced December 1, 2025, lower doses do cost less: 2.5 mg is $299 per month, 5 mg is $399, and 7.5 mg through 15 mg are all $449 ^[20].

Zepbound single-dose vial	LillyDirect Self Pay Journey
2.5 mg	$299/month
5 mg	$399/month
7.5 mg	$449/month
10 mg	$449/month
12.5 mg	$449/month
15 mg	$449/month

The lower prices for the 7.5 mg and higher vials apply only on the first fill and when prescriptions are refilled within 45 days of the previous delivery. Outside that window, the 12.5 mg vial is $849 and the 15 mg vial is $1,049 ^[20]. These are direct-to-consumer self-pay prices, not list prices and not insurance prices.

What do guidelines and reviews say about lowering or stopping?

The joint guidance statement from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition, developed using the GRADE approach, gives a strong recommendation to continue obesity medications during weight maintenance ^[21].

A review in Diabetes, Obesity and Metabolism found that weight regain after stopping a GLP-1 is front-loaded into the early months after cessation, and that lower-dose maintenance, reduced-frequency dosing, or a gradual taper may attenuate that early regain compared with abrupt discontinuation ^[22].

A narrative perspective on what it calls adaptive maintenance reaches similar conclusions: continued medication currently has the strongest direct evidence for limiting regain, while potential strategies include monitored dose reduction with predefined re-escalation criteria, switching to an oral agent, reduced-frequency dosing, and intermittent rescue therapy. The stated goal is finding the minimum effective maintenance intensity for each person, and the authors note that using early appetite and satiety signals to catch relapse still requires prospective validation ^[26].

What happens if a full dose is restarted after a gap?

A published case report describes a 51-year-old woman who developed severe nausea, vomiting, and diarrhea one day after restarting semaglutide 2.4 mg following a five-week interruption during Ramadan. She had previously tolerated the drug for about a year, but this time she was hospitalized ^[23].

Butsch’s framing applies here as well: adjusting a dose is a conversation with the prescriber, who knows the medication and the patient’s situation. As he put it, adjusting the dose to individual needs is not microdosing, it is the art of practicing medicine ^[15].

Sources

1. Novo Nordisk. Wegovy (semaglutide) prescribing information.
2. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
3. The Lancet. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. June 6, 2026.
4. Nature Medicine. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
5. PubMed. From Induction to Maintenance? Rethinking GLP-1-Based Obesity Pharmacotherapy in the Era of Oral Agents.
6. Medscape Medical News. De-escalating GLP-1s to every-2-weeks maintenance option. November 5, 2025.
7. PubMed. Reduced-frequency GLP1 therapy maintains weight, body composition, and metabolic syndrome improvements: a case series.
8. Healio. Weight loss can persist after reducing GLP-1 dosing frequency. April 11, 2026.
9. Medical Xpress. Some patients keep weight off with fewer GLP-1 injections, study finds. March 6, 2026.
10. Obesity. Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy. 2025.
11. Diabetes, Obesity and Metabolism. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. 2025.
12. Cedars-Sinai. Microdosing semaglutide: does it work for weight loss? May 26, 2026.
13. STAT. GLP-1 microdosing is popular, but there’s little evidence it works. May 29, 2026.
14. Los Angeles Times. What’s the deal with microdosing Ozempic? June 23, 2026.
15. Cleveland Clinic. Should you microdose GLP-1 medications? July 31, 2026.
16. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products.
17. Drug Discovery and Development. FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide.
18. Diabetes Care. One size does not fit all: understanding microdosing semaglutide for diabetes in multidose pens. March 2025.
19. Novo Nordisk. Wegovy price guide.
20. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials. December 1, 2025.
21. PubMed. Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.
22. PubMed. Early weight regain after GLP-1 receptor agonist discontinuation: mechanisms and implications for treatment de-escalation strategies.
23. PubMed. Severe gastrointestinal intolerance after resuming maintenance-dose semaglutide following Ramadan-related treatment interruption: a case report.
24. PubMed. Reduced-frequency GLP-1 dosing may sustain treatment effects.
25. PubMed. The “microdosing” dilemma: balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
26. PubMed. Adaptive maintenance after incretin-induced weight loss: moving beyond the continue-or-stop paradigm.